



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 September 2017  
EMA/765134/2016  
Stakeholders and Communication Division

## Agenda - Session on antimicrobial resistance EMA Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting

19 September 2017, 08:30hrs to 17:15hrs – meeting room: 2A

### Background

The emergence and increase of microbes resistant to antimicrobial treatments is a global public health concern that poses a risk to the effective treatment of infectious diseases. Combatting this threat, particularly resistance to antibiotics, is a high priority for the European Medicines Agency (EMA) and the European medicines regulatory network.

Responding to a high interest from PCWP and HCPWP, EMA joined efforts with the European Centre for Disease Prevention and Control (ECDC) to prepare and informative session intended to raise awareness of ongoing initiatives and stimulate an exchange of ideas with patient, consumer and healthcare professional organisations on how to join efforts for improving communication, education and training.

### Objectives

1. Raise awareness of the work of EU Institutions, member states and WHO in the fight against AMR.
2. Enhance understanding of how EMA and ECDC can support the European and global-level fight against AMR.
3. Discuss how to coordinate efforts on awareness and empowerment by patients, consumers and healthcare professionals.



19 September 2017

08:30	Registration and reimbursement arrangements	
08:50	Welcome Health and safety information Interests disclosure	J. Garcia Burgos (EMA)
09:00	Introduction and objectives	
09:10	remarks	
<b>Session 1: Setting the scene</b>		
Chair: J. Garcia Burgos (EMA)		
09:20	<ul style="list-style-type: none"> <li>Key note addresses by EC and WHO HQ</li> </ul>	M. Plantady (EC) C. Pessoa da Silva (WHO)
10:00	<i>Coffee</i>	
<b>Session 2: EMA/ EU Regulatory Network – what we do and don't do</b>		
Chair: M. Cavaleri (EMA)		
10:15	<ul style="list-style-type: none"> <li>Human side                             <ul style="list-style-type: none"> <li>Antimicrobial drug development : Role and importance of the regulatory requirements</li> <li>EMA activities in the fight against AMR</li> </ul> </li> <li>Veterinarian side                             <ul style="list-style-type: none"> <li>Contribution within the EU Regulatory Network</li> <li>Activities related to the use of antimicrobials in animals</li> </ul> </li> </ul>	M. Powell (MHRA/CHMP-IDWP) M. Cavaleri (EMA)  H. Jukes (VMD/CVMP) J. Torren Edo (EMA)
12:00	<i>Lunch</i>	
<b>Session 3: ECDC – focus on consumption data and campaign support</b>		
Chair: H. Goossens (University of Antwerp)		
13:00	<ul style="list-style-type: none"> <li>ECDC work on AMR                             <ul style="list-style-type: none"> <li>Antimicrobial Resistance and Healthcare-associated Infections Programme (ARHAI) at ECDC</li> <li>Collaboration with EMA and EFSA, TATFAR, WAAW and international partners</li> </ul> </li> <li>European Antibiotic Awareness Day (EAAD)                             <ul style="list-style-type: none"> <li>Engaging with countries and stakeholders</li> <li>Resources available – toolkits and training module</li> <li>EAAD 2017 – 10th edition, how to get involved</li> </ul> </li> <li>National perspective: UK and Antibiotic Guardian</li> </ul>	G. Mancarella (ECDC)  A. Nilsson (ECDC)  D. Ashiru-Oredope (ARHAI/PHE)
14:45	<i>Coffee</i>	

**Session 4: How to join efforts for improving communication, education and training**

Co-chairs: J. Garcia Burgos (EMA) / K. Immonen (PCWP)

15:00	<ul style="list-style-type: none"> <li>• Share ongoing initiatives from patients, consumers and HCPs organisations             <ul style="list-style-type: none"> <li>– EPHA AMR campaign</li> <li>– Prescription by general practitioners/family physicians</li> <li>– The community pharmacy contribution to tackling antimicrobial resistance</li> <li>– Nurses’ role in antimicrobial stewardship</li> <li>– ESCMID initiatives to combat antimicrobial resistance and the inappropriate use of antibiotics</li> </ul> </li> <li>• How to capitalise from this information session?</li> </ul> <p>Panel discussion with contributions from EC/WHO/EMA/ECDC/EFSA</p>	<p>S. Marschang (EPHA)  W. Marrocco (EFPC)  J. Wilkinson (PGEU)</p> <p>B. Oomen (ESNO)  M. Akova (ESCMID)</p> <p>P. Stella (EFSA)</p> <p>G. Mancarella / A. Nilsson (ECDC)  J. Garcia Burgos (EMA)  C. Pessoa da Silva (WHO)  M. Plantady (EC)</p>
17:00	Final remarks	J. Garcia Burgos (EMA)
17:15	<i>End of meeting</i>	